Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

Anna Viola, Giuseppe Costantino, Antonino Carlo Privitera, Fabrizio Bossa, Angelo Lauria, Laurino Grossi, Maria Beatrice Principi, Nicola Della Valle, Maria Cappello

Conflict-of-interest statement: The authors declare no conflicts of interests. None of the authors have any financial or other relations that could lead to a conflict of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Submitted for peer review: September 5, 2016
Peer-review started: September 5, 2016
First decision: October 20, 2016
Revised: December 30, 2016
Accepted: January 16, 2017
Article in press: January 18, 2017
Published online: May 6, 2017

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Submitted for peer review: September 5, 2016
Peer-review started: September 5, 2016
First decision: October 20, 2016
Revised: December 30, 2016
Accepted: January 16, 2017
Article in press: January 18, 2017
Published online: May 6, 2017

Abstract

AIM
To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs.
Viola A et al. Economic impact of infliximab short infusion

METHODS
All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated.

RESULTS
One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration of disease was of 53 mo and mean age of pts at diagnosis was of 34 years (SD: ± 13). Adverse infusion reactions were reported in less than 4% both before and after short infusion. The total number of infusions across the selected centers was of 2501 (30.5% short infusions). In the analyzed cohort, 1143 h were saved (762 in the infusion and 381 in observation phases) through the rapid IFX infusion protocol. This time saving (-15% compared to the standard protocol in infusion phase) represents, from the hospital perspective, an opportunity to optimize infusion unit capacity by allocating the saved time in alternative cost-effective treatments. This is the case of opportunity cost that represents the value of foregone benefit which could be obtained from a resource in its next-best alternative use. Hence, an extra hour of infusion in the case of standard 2-h IFX represents a loss in opportunity to provide other cost effective services. The analysis showed that the short infusion increased the infusion units capacity up to 50% on days when the IFX infusions were scheduled (infusion phase). Furthermore, the analysis showed that the short IFX infusion protocol leads to time savings also in the post-infusion phase (observation) leading to a time saving of 10% on average among the analyzed centers. Finally, the short infusion protocol has been demonstrated to lead to indirect cost savings of €138/patient (average €17.300 on the whole cohort).

CONCLUSION
A short IFX infusion protocol can be considered time and cost saving compared to the standard infusion protocol both from the hospital’s perspective, as it contributes to increase infusion units capacity, and the patients’ perspective, as it reduces indirect costs and the impact of treatment on everyday life and work productivity.

Key words: Infliximab; One-hour infusion; Cost savings; Economic impact; Multicenter study

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Infliximab (IFX) is a monoclonal antibody anti-tumour necrosis factor (anti-TNF) effective in inducing and maintaining remission of moderate to severe luminal and fistulizing Crohn’s disease (CD) and of moderate to severe refractory ulcerative colitis (UC). It is also used to treat rheumatoid arthritis and moderate to severe psoriasis. IFX is usually administered intravenously at a dose regime of 5 mg/kg as a 2-h infusion followed by a monitoring time of 2 h thereafter. This standard practice has been adopted in order to minimize infusion reactions, which are known to occur during infusion and later in the immediate post infusion period. However, the standard practice has a significant impact in the setting of limited healthcare resource in terms of dedicated areas (infusion units), facilities and, mostly, time. Short infusion (1-h) protocols have been found safe in patients with rheumatoid arthritis recently. A shorter infusion time of one hour has been used also in inflammatory bowel diseases (IBD) patients, in maintenance therapy and who tolerated a 2-h infusion without adverse events, in referral centers. Tolerability of one hour infusion has also been reported for 10 mg/kg IFX. One hour infusions are less time-consuming and might be considered in clinical practice to improve patients’ quality of life and compliance to IFX therapy. Moreover, infusion therapy is also costly for patient in terms of expenses related to travel to the hospital and of hours spent in the infusion clinic (work loss). At present evidence on cost savings of short infusion is scanty. We have previously confirmed in a pilot study that shortening the infusion protocol to 1 h is equally safe and positively affects quality of life. This paper analyzes the impact of short IFX infusion on hospital resource utilization and costs, both in terms of time saving and increased infusion unit capacity. In addition, we provide evidence of indirect patient-related cost savings.

INTRODUCTION
Infliximab (IFX) is a chimeric monoclonal antibody anti-tumour necrosis factor (anti-TNF) effective in inducing and maintaining remission of moderate to severe luminal and fistulizing Crohn’s disease (CD) and of moderate to severe refractory ulcerative colitis (UC). It is also used to treat rheumatoid arthritis and moderate to severe psoriasis. IFX is usually administered intravenously at a dose regime of 5 mg/kg as a 2-h infusion followed by a monitoring time of 2 h thereafter. This standard practice has been adopted in order to minimize infusion reactions, which are known to occur during infusion and later in the immediate post infusion period. However, the standard practice has a significant impact in the setting of limited healthcare resource in terms of dedicated areas (infusion units), facilities and, mostly, time. Short infusion (1-h) protocols have been found safe in patients with rheumatoid arthritis recently. A shorter infusion time of one hour has been used also in inflammatory bowel diseases (IBD) patients, in maintenance therapy and who tolerated a 2-h infusion without adverse events, in referral centers. Tolerability of one hour infusion has also been reported for 10 mg/kg IFX. One hour infusions are less time-consuming and might be considered in clinical practice to improve patients’ quality of life and compliance to IFX therapy. Moreover, infusion therapy is also costly for patient in terms of expenses related to travel to the hospital and of hours spent in the infusion clinic (work loss). At present evidence on cost savings of short infusion is scanty. We have previously confirmed in a pilot study that shortening the infusion protocol to 1 h is equally safe and positively affects quality of life. This paper analyzes the impact of short IFX infusion on hospital resource utilization and costs, both in terms of time saving and increased infusion unit capacity. In addition, we provide evidence of indirect patient-related cost savings.

MATERIALS AND METHODS
All patients who received 1 h infusion of IFX from
March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Written informed consent was obtained prospectively from each patient. For each patient, demographic, clinical and infusion related data were collected retrospectively on a shared dedicated database (Excel). All patients received the dose of 5 mg/kg. Optimization of therapy was achieved by shortening the interval between infusions.

On the basis of available data, the potential benefits related to the short infusion protocol were considered both in terms of potential time saving and increased infusion unit capacity. As there was no difference in terms of drug costs, nursing and specialist service costs in both protocols, it was not possible to assess the short infusion protocol impact in direct costs terms. Instead, it was possible to estimate the related productivity loss/gain of the two different protocols. Indirect costs were expressed in terms of working hours lost due to the infusion. Indirect costs were calculated on the basis of productivity lost according to the human capital approach. The value was collected through available literature\(^{16}\). In particular, the indirect costs were calculated by multiplying infusion hours by work/hour/loss in order to assess the difference between the two different protocols. Details on infusion time for both protocols are reported in Table 1. Furthermore, we assessed the impact related to the short infusion protocol on the units capacity in terms of number of treated patients; a questionnaire was sent to the participating centers to collect data on the number of patients submitted to IFX infusion/day by adopting the short infusion schedule which was compared with the same data when a standard infusion time was used. This comparison was possible just in one center (University Hospital Palermo); because of different work organization, this value was not available in other centers. Continuous variables were expressed as mean ± standard deviation, and categorical variables as absolute frequency and percentage. The comparison between continuous variables was made by the Student t-test and categorical variables were analysed by using the chi-square test. Statistical significance was reached when \(P\) was < 0.05. Data were analyzed using the statistics software SPSS version 15.0.

**RESULTS**

A total of 125 patients with IBD were included in the study, 64 with UC and 61 with CD. Seventy-one (61.6%) were male and 48 (38.4%) were female. Mean age of patients at diagnosis was 34 years (SD: ± 13). Characteristics of the patients are given in Table 2. Median duration of disease was of 53 mo (IQR: 16-110.5) and median duration of follow-up was 34 mo. The mean number of total infusion/patient was 20 (range: 4-60) and the mean number of short infusions was 6.1 (range: 1-19). Patients were shifted to one-hour infusion after a median interval of 21 mo. Median follow-up of patients in short infusion was 12 mo. Indications for IFX were steroid-dependence in 61.6%, steroid-resistance in 8%, failure of thiopurines (9.6%), fistulizing disease (5.6%), rescue therapy in severe UC (2.4%). A total of 33 patients (26.4%) were taking steroids. Concomitant use of immunomodulators (azathioprine or methotrexate) was reported in 28 patients (22.4%). Seventy-five patients received mesalamine.

Fifty-seven (45.6%) patients received no premedication. A total of 68 patients (54.4%) was submitted to premedication: 51 (40.8%) with steroids, 1 with antihistaminic (0.8%) and 16 patients with both (12.8%). Details are reported in Table 3.

Adverse infusion reactions were observed in about 4% of patients both before (4 patients) and after short infusion (5 patients). Among the 9 patients who experienced an infusion reaction we recorded 7 being acute, 1 acute-severe, 1 delayed. Adverse infusion reactions occurred at a median of 3 (IQR 3-23) mo after the first infusion. In patients with mild or moderate infusion reaction the infusion was interrupted, medical therapy was administered and after resolution of symptoms, infusion was restarted slowly. The use of premedication was not significantly associated with different rates of infusion reactions. Opportunistic infections occurred in 5 patients (4%) both before and after short infusion. Opportunistic infections occurred at a median of 32 (IQR: 18-39) mo after the first infusion. No death occurred. Details are given in Table 3.

The total number of infusions across the selected centers was of 2501 (30.5% short infusions). We therefore calculated the potential related benefits both in

| Table 1 | Traditional vs short infusion protocols time duration |
|---------|-----------------------------------------------|
|         | Traditional infusion (min) | Short infusion (min) |
| Observation phase | 90 | 60 |
| Infusion phase | 120 | 60 |
| Total minutes | 210 | 120 |
| Total hours | 3.5 | 2 |

| Table 2 | Demographics and characteristics of patients |
|---------|-----------------------------------------------|
| Gender | Male 77 (61.6%) | Female 48 (38.4%) |
| Mean age at diagnosis | 33.6 (range: 10-80) |
| Smoke | No 76 (70.8%) | Yes 26 (20.8%) |
| Former | No 106 (84.8%) | Yes 19 (15.2%) |
| Family history | No 116 (92.8%) | Yes 9 (7.2%) |
| Characteristics of disease | Ulcerative colitis 64 (51.2%) | Crohn’s disease 61 (48.8%) |
| Duration of disease at 1st infusion (median) | 52 mo (IQR: 16-110.5) |
| Duration of follow-up (median) | 34 mo (IQR: 19-55.5) |
The analysis showed that the short IFX infusion protocol leads to time savings also in the post-infusion phase (observation) by leading to a time saving of 10% on average among the analyzed centers. Finally, the short infusion protocol has been demonstrated to lead to indirect cost savings of €138/patient (average -€17.300 on the whole cohort). In Table 4 we report the details on the split between short and traditional infusion.

**DISCUSSION**

IFX therapy is effective in the management of IBD both in the induction and in maintenance of remission, in preventing the rate of postoperative recurrence in CD and in reducing the need of hospital admission and surgery. Recently, IFX therapy has been shown to promote mucosal healing, an outcome strongly related to long-term remission[17]. This treatment is widely used, since about 15%-20% of patients with IBD are currently on anti-TNFs and usually for long periods of time since most patients will be kept on maintenance therapy[18] for 12-24 mo or even longer. IFX is administered at a dose of 5 mg/kg as a 2-h infusion followed by a monitoring time of additional 2 h. Efficacy and safety of shorter IFX infusion times have been recently demonstrated both in the setting of rheumatological disorders and IBD in observational studies. A good tolerability profile of one-hour infusion (3 or 5 mg/kg) was reported first in rheumatoid arthritis, psoriatic arthritis and ankilosyng spondylitis patients[19] and recently for IBD patients who tolerated a 2-h infusion without adverse reactions (acute or delayed)[20]. A meta-analysis has confirmed that rapid IFX infusions of ≤ 1-h duration are safe and not associated with increased risk of infusion reaction when compared to standard infusions in patients with IBD, rheumatoid arthritis, spondylarthropathy and psoriatic disease[20].

Short IFX infusion could also influence patients’ quality of life. Prinici et al[21] reported an improvement in social and job quality of life in patients treated with 1-h infusion of IFX. However, though some Authors[21] have suggested the possibility of reducing costs for the healthcare provider of patient daycare attendance combined with medical staffing requirements, a pharmacoeconomic evaluation of the accelerated infusion protocol has never been approached. To our knowledge, data in the literature on economic impact of one-hour infusion in IBD patients comparing standard infusion are scanty. Only one study, carried on in the United States, has been published so far, enrolling patients on accelerated infusions (both 90 min and 60 min long) at various IFX dosage[22]. This study focused on hospital cost savings, by estimating the cost required to deliver infusions over 120-min vs using the accelerated infusion times: 118 h of infusion time and $53632 were saved by using the accelerated protocols (P < 0.001).

Kuin et al[23] evaluated both safety and costs of home-
based IFX infusion as an alternative to hospital-based infusions for the management of CD patients. Home-based IFX infusions were associated with a cost saving of €55 per infusion. Another study, conducted in a small pediatric population in United States, obtained similar results. Home-based therapy, though fascinating, is not applicable to all health care systems. In Italy, there are also regional differences.

Our findings suggest that in terms of indirect costs a short IFX infusion protocol in the hospital can be considered time and cost saving in comparison to the traditional infusion protocol. Our analysis could not assess differences in direct costs since costs of devices and hospital staff were similar whatever protocol is used.

The strengths of our study are: Firstly, the assessment of indirect costs of the two different infusion protocols which has never been approached and that is the most relevant from the patients’ perspective; secondly, the evaluation of the improvement of organizational efficiency in terms of health care utilization resources. The use of short infusions seems to increase the unit capacity up to 50%, though this evaluation was possible only in one of the participating centers.

Our study has however some limitations. Firstly, the impact on hospital resource utilization was assessed in only one center. It could be argued that this result may not be representative of all the involved centres as it depends also on hospitals’ specific organizational features. Secondly, the retrospective methodology of our study could influence the accuracy of the results. However, detailed notes of infusion characteristics were made at the time of each infusion in all participating centers so that underreporting was not expected. Finally, an activity based costing approach would be recommended in order to assess the “real” direct cost impact from the hospital perspective.

In conclusion, this study can be considered an important step in the economic evaluation of the short infusion protocol within the Italian context, although it would be recommended to perform a full economic evaluation considering both costs and related outcomes in order to provide comprehensive evidence based data useful for decision makers at local level.

A short IFX infusion protocol can be considered time and cost saving in comparison to the standard 2-h infusion protocol as it contributes to increase infusion units capacity up to 50%. From the patients’ perspective, reduces indirect costs and the impact of treatment on everyday life and work productivity. On the basis of our study, we believe that the one hour IFX infusion protocol in patients in stable maintenance therapy should be implemented in clinical practice.

**COMMENTS**

**Background**

Infliximab (IFX) is a chimeric monoclonal antibody anti-tumour necrosis factor effective in inducing and maintaining remission of moderate to severe luminal and fistulizing Crohn’s disease and of moderate to severe refractory ulcerative colitis. It is also used to treat rheumatoid arthritis and moderate to severe psoriasis. IFX is usually administered intravenously at a dose regimen of 5 mg/kg as a 2-h infusion followed by a monitoring time of 2 h. This standard practice has been adopted in order to minimize infusion reactions. Previous reports have shown that shortening the infusion to one hour is equally safe. The key-question addressed by this manuscript is whether this accelerated infusion protocol is cost-saving both on the hospital’s and on the patient’s perspective.

**Research frontiers**

Data in the literature on economic impact of one-hour infusion in inflammatory bowel diseases patients are scanty. Only one study, carried on in the United States, focused on hospital cost savings, by estimating the cost required to deliver infusions over 120-min vs using the accelerated infusion times.

**Innovations and breakthroughs**

The methodology adopted in this research explores the potential benefits related to the short infusion protocol both in terms of potential time saving and increased infusion unit capacity. Indirect costs were expressed in terms of working hours lost due to the infusion. This approach has been recently applied in pharmacoeconomic research.

**Applications**

The future application of the research could be the use of the accelerated infusion protocol not only with the infliximab originator molecule, but also with biosimilars. This could significantly reduce direct and indirect costs, increase infusion units’ capacities and allow access of increased number of patients to effective therapy even in low income countries.

**Terminology**

Standard infusion practice requires dedicated areas (infusion units), facilities and time. Saving time is an opportunity to optimize infusion unit capacity by allocating the saved time in alternative cost-effective treatments or by increasing the number of treated patients. Indirect costs reflect patients’ expenses related to travel to the hospital and of hours spent in the infusion clinic (work loss).

**Peer-review**

Manuscript is well written and easy to follow.

**REFERENCES**

1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]

---

Table 4  Infusion time and indirect cost savings: Traditional vs short infusion protocol

|                      | w/out S1 (min) | w S1 (min) | Delta (min) | Saving (min) | Delta % | Hours | Saving indirect costs (€) |
|----------------------|---------------|-----------|-------------|--------------|---------|-------|--------------------------|
| Infusion time        | 300120        | 254400    | -45.72      | -45720       | -15%    | -762  | -11.525                  |
| Post infusion time   | 225090        | 202220    | -22.86      | -22860       | -10%    | -381  | -5.763                   |
| Total time           | 525210        | 456630    | -68.58      | -68580       | -13%    | -1143 | -17.288                  |
| Costsaving/patient   |               |           |             |              |         | -9    | -138                     |
Viola A et al. Economic impact of infliximab short infusion

2 Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamrn MA, Korzenik JR, Lashmer BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]

3 Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colonel JB. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050156]

4 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weinman M, Smolen J, Emery P, Hartmann G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939 [PMID: 10622295 DOI: 10.1016/S0140-6736(00)5246-05]

5 Reik C, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CF, EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374 [PMID: 16226614 DOI: 10.1016/S0140-6736(05)67566-6]

6 Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 [PMID: 9321530 DOI: 10.1056/NEJM199710093371502]

7 Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-920 [PMID: 15476155]

8 Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezaan RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405 [PMID: 10228190 DOI: 10.1056/NEJM199903063401804]

9 Cheifetz A, Smedley A, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-1324 [PMID: 12818276 DOI: 10.1111/j.1572-0241.2003.007457.x]

10 Buch MH, Breyer D, Lindsay S, Rees-Evans B, Faulchough A, Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006; 45: 485-486 [PMID: 16352636 DOI: 10.1093/rheumatology/kei273]

11 Reynaudet C, Ferrante M, Fiddler H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. J Am Gastroenterol 2011; 106: 778-785 [PMID: 21407184 DOI: 10.1038/ag.2011.61]

12 Van Assche G, Vermeire S, Noman M, Ambart C, Weyts E, Vleminckx A, Vermeys MJ, Rutgeerts P. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis 2010; 4: 329-333 [PMID: 21122522 DOI: 10.1016/j.crohns.2009.12.012]

13 Babouri A, Robin X, Filippi J, Hébuterne X, Bigard MA, Peyrin-Biroulet L. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. J Crohns Colitis 2014; 8: 161-165 [PMID: 23994253 DOI: 10.1016/j.crohns.2013.08.004]

14 Principi M, Losurdo G, La Fortezza RF, Lopolito P, Lovero R, Grillo S, Bringiotti R, Ierardi E, Di Leo A. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation. J Gastrointestin Liver Dis 2015; 24: 165-170 [PMID: 26114755 DOI: 10.15403/jgl.2014.1121.242.text]

15 Cappello M, Maza M, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Almasio PL. Safety of infliximab (ix) one-hour infusion in inflammatory bowel disease (IBD): a multicenter study from southern Italy. DLD 2015; 47 (S 2): e131

16 Marcellusi A, Viti R, Capone A, Mennini FS. Cost of illness probabilistic methodology to assess direct and indirect costs of HCV-related diseases in Italy. Pharmacoeconom Ital Res Arctic 2014; 16: 23 [DOI: 10.4027/s40276-014-0020-9]

17 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-455 [PMID: 17369375 DOI: 10.1136/gut.2005.088732]

18 Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2006; 134: 402-413 [PMID: 14762776 DOI: 10.1053/j.gastro.2003.11.014]

19 van Vollenhoven RF, Gullström E, Klareskog L. Feasibility of 1 hour infliximab infusions. Ann Rheum Dis 2005; 64: 654 [PMID: 15769930 DOI: 10.1136/ard.2005.037590]

20 Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther 2013; 38: 365-376 [PMID: 23815183 DOI: 10.1111/apt.12389]

21 Bhat S, Sharma D, Doherty P, Tham TC, Caddy GR. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010; 16: 1922-1925 [PMID: 20848465 DOI: 10.1002/ibd.21279]

22 McConnell J, Parvulescu-Codrea S, Behm B, Hill B, Dankle E, Finke K, Snyder K, Tuskey A, Cox D, Woodward B. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastroenterol Pharmacol Ther 2012; 3: 74-82 [PMID: 23515325 DOI: 10.4292/wjgpt.v3.i5.74]

23 Kuni S, Stolte SB, van den Brink GR, Ponsioen CY, Fockens P, D’Haens GR, Löwenberg M. Short article: Remicade infusions at home: an Economic impact of infliximab short infusion. J Crohns Colitis 2014; 8: 161-165 [PMID: 23994253 DOI: 10.1016/j.crohns.2013.08.004]

24 Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr Gastroenterol Nutr 2005; 40: 67-69 [PMID: 15625429 DOI: 10.1097/00005176-200501000-00012]

P- Reviewer: Okello M, Puri K, Vradelis S S- Editor: Song XX L- Editor: A E- Editor: Lu YJ
